Monthly Newsletter

Dualsystems Biotech and NiKem Research are pleased to announce the formation of a strategic alliance to jointly offer their respective drug/target profiling and drug discovery services to their clients.

The ever increasing complexity and expense of drug discovery requires an excellent understanding of molecular targets and mechanism of action in disease early in the research phase to match high quality compound optimisation. Dualsystems offers a proprietary suite of technologies for drug and target profiling from a client's phenotypic assays. Based on its advanced platforms to discover protein interactions, mechanism of action and target network, information is generated at an early stage of hit-to-lead, lead optimisation or candidate selection. These skills are complemented by the synthetic and medicinal chemistry expertise, the ADMET & DMPK and early toxicology services that NiKem has been providing to its clients over the last 10 years. The combined skills that Dualsystems and NiKem can now offer via a single point of contact make for a highly efficient drug discovery engine. All generated intellectual property is assigned to the client.

Dualsystems' and NiKem's combined technologies will help clients speed up their drug development by providing real-time information about drug candidates, their targets, their mechanisms of action and allow for a seamless downstream development of the molecules of interest.

About NiKem Research
NiKem was founded in 2001 as a spin-off from the GSK Research Centre in Baranzate, Italy and has a staff of about 55 employees. NiKem established its international reputation as a reliable, high quality drug discovery service partner, based on decades of R&D experience and proved capacity. NiKem offers a full range of synthetic, medicinal, and analytical chemistry, biochemical pharmacology, and extensive ADMET & DMPK services, early toxicology and GLP and GCP bioanalysis. NiKem's mission is to cost effectively and rapidly translate customers' discovery biology output into robust preclinical candidates.

About Dualsystems Biotech
Dualsystems is a privately held biotechnology company established in 2001 as a spin-off from the University Zurich, Switzerland. Dualsystems has positioned itself as a leading provider of screening services for industry and academia, specializing in drug and target profiling, protein interaction discovery and in situ protein complex analysis. To complement its drug/target interaction discovery services Dualsystems offers mass spectrometry-based products and services in the area of interactive proteomics and a set of proprietary screening platforms for the discovery of membrane protein interactions.